---

Visit the Cellceutix Website.
 
Leave a comment in the CTIX blog






 

---

Cellceutix Pharmaceuticals, Inc. (OTCBB: CTIX), located outside of Boston in Beverly, MA, is an emerging bio-pharmaceutical company in the business of developing small molecule therapies in areas of unmet medical need. Their primary efforts are in cancer and inflammatory disease, but also have another compounds in the pipeline that are being formulated to treat psoriasis and autism. Cellceutix flagship product, Kevetrin, is being developed to treat cancers that are resistant to standard treatments. The company’s portfolio of product candidates in pre-clinical development includes two anti-cancer agents targeting multiple tumors; one candidate targeting psoriasis; one candidate targeting rheumatoid arthritis; one candidate with potential for indications of osteo-arthritis/asthma; one candidate with a potential for indications of neurological disorders for the treatment of Multiple Sclerosis, Lou Gehrig Disease, and/or Parkinson’s Disease; and a small molecule with potential for development to treat hypertensive emergency.

Learn more about the Cellceutix pipeline:

Kevetrin for multi-drug resistant cancers | Prurisol for psoriasis | KM-391 for autsim

Their business strategy is well-described by their company slogan “Compounds for Cures.” Cellceutix has kept a “low profile” as they have been developing their products and funding internally to maintain shareholder value by virtue of no dilution. By biotechnology standards, their pipeline of products is moving forward rapidly through an experienced management and development team with years of experience in researching, developing and marketing pharmaceuticals. Cellceutix was delisted to the pinksheets at the end of 2010 due to lack of market maker activity, but intends to ramp-up exposure and return to the Bulletin Boards in the coming months. From a investors standpoint, the delisting caused a drop in share price which is offering a “value opportunity” at these levels. CTIX was trading near 80 cents per share less than one year ago.

HISTORY OF CELLCEUTIX CORPORATION

Cellceutix was established in May of 2007 by Chief Scientific Officer, Dr. Krishna Menon.

Dr. Krishna Menon’s experience and accolades are impressive to say the least. Dr. Menon has nearly 40 years experience in drug development for academia and industry. Some of the highlights of Dr. Menon’s career include:

• Chief Government Veterinarian for a major Parish in Jamaica
• Director of Agriculture for the Cayman Islands in the British Caribbean
• Research Scientist under the acclaimed oncologist, Dr. Emil Frei, at the Dana Farber Cancer Research Institute
• Senior Research Scientist, In Vivo Research (Cancer), at Bayer Pharmaceuticals (Miles Laboratories)
• Operating his own veterinary oncology and drug development consultancy practice
• Group Leader, Cancer In Vivo Research and Clinical Development, for Eli Lilly
• Recipient of the President’s Recognition Award by Eli Lily (This is an award not bestowed annually, but rather on only special occasions)
• PhD from Kerala University and Post Doctoral at Dana Farber (Harvard University)

The final component of Cellceutix solid corporate structure is their Chief Financial Officer, Leo Ehrlich. Mr. Ehrlich has been with Cellceutix since June of 2007. A Certified Public Accountant, Mr. Ehrlich also his his BBA from Bernard Baruch College of the City University of New York and sits on the board at StatSure Diagnostic Systems, Inc. as their Chief Financial Officer. Before coming to Cellceutix, Mr. Ehrlich Mr. Ehrlich was the CFO and a director of Nanoviricides, Inc. from June 1, 2005. until May 2007.

---

SHARE STRUCTURE (approximate as of January 10, 2010)

• Authorized Shares:  300,000,000
• Outstanding Shares:  98,000,000
• Float: 40,000,000

TRANSFER AGENT

Pacific Stock Transfer Co.
4045 South Spencer Street
Suite 403
Las Vegas, NV 89119
Tel: (702) 361-3033
Fax: (702) 433-1979

E-mail: [email protected]

CONTACT INFORMATION

Cellceutix Corporation
100 Cumming Center
Suite 151-B
Beverly, MA 01915

Phone: 978-633-3623
Fax: 978-921-6564
Email: [email protected]

Website: www.cellceutix.com

Post a comment in the CTIX blog

Cellceutix Corp. (CTIX) Stock Quote and News:

---

---

Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated on several occasions for news dissemination and journalism services from Cellceutix Corporation and holds a total of 100,000 shares of 144 restricted stock of Cellceutix Corporation, none of which has been sold to date, nor intends to be sold in the near term. Prior compensation is listed in our full disclosure. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/?page_id=190.